# Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer

> **NCT02690948** · PHASE1,PHASE2 · COMPLETED · sponsor: **Anne Chang** · enrollment: 16 (actual)

## Conditions studied

- Skin Basal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Vismodegib

## Key facts

- **NCT ID:** NCT02690948
- **Lead sponsor:** Anne Chang
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-01
- **Primary completion:** 2017-11-30
- **Final completion:** 2018-08-29
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2019-03-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02690948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02690948, "Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02690948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*